Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma

Journal of the American College of Surgeons

Volumn 196, Issue 4, 2003, Pages 573-578

  Shimada, Hideaki ^a   Nabeya, Yoshihiro ^a   Okazumi, Shin ichi ^a   Matsubara, Hisahiro ^a   Miyazawa, Yukimasa ^a   Shiratori, Tooru ^a   Hayashi, Hideki ^a   Gunji, Yoshio ^a   Ochiai, Takenori ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

EID: 0037388473     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(02)01905-1     Document Type: Article

References (31)

1. Isono K, Onoda S, Ishikawa T, et al. Studies on the causes of deaths from esophageal carcinoma. Cancer 1982;49:2173-2179.
2. The Japanese Society of Esophageal Disease. Comprehensive registry of esophageal cancer in Japan (1995, 1996, 1997). 2nd ed. Tokyo, Japan: The Japanese Society of Esophageal Disease; 87.
3. Daly JM, Karnell LH, Menck HR. National cancer database report on esophageal carcinoma. Cancer 1996;78:1820-1828.
4. Aloia TA, Harpole DH, Reed CE, et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001;72:859-866.
5. Lopez JB, Royan GP, Lakhwani MN, et al. CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies. Int J Biol Markers 1999;14:172-177.
6. Clark GW, Ireland AP, Hagen JA, et al. Carcinoembryonic antigen measurements in the management of esophageal cancer: an indicator of subclinical recurrence. Am J Surg 1995;170: 597-600.
7. Kim YH, Ajani JA, Ota DM, et al. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer 1995;15:451-456.
8. McKnight A, Mannell A, Shperling I. The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal cancer. Br J Cancer 1989;60:249-251.
9. Munck-Wikland E, Kuylenstierna R, Lindholm J, Wahren B. Carcinoembryonic antigen, CA 19-9 and CA 50 in monitoring human squamous cell carcinoma of the esophagus. Anticancer Res 1990;10:703-708.
10. Munck-Wikland E, Kuylenstierna R, Wahren B, et al. Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer 1988;62:2281-2286.
11. Shimada H, Takeda A, Arima M, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 2000;89:1677-1683.
12. Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001;92:663-669.
13. Shimada H, Takeda A, Nabeya Y, et al. Prognostic signifcance of serum thymidine phosphrylase in the patients with esophageal squamous cell carcinoma. Cancer 2002;94:1947-1954.
14. Shimada H, Okazumi S, Matsubara H, et al. Prognostic significance of serum p53 antibodies in the patients with esophageal squamous cell carcinoma. Surgery 2002;132:41-47.
15. Pujol JL, Grenier J, Daures JP, et al. Serum fragment of cyrokeratin subunit 19 measured by CYFRA21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53:61-66.
16. van der Gaast A, Schoenmakers CH, Kok TC, et al. Evaluation of a new tumor marker in patients with non-small cell lung cancer: cyfra21-1. Br J Cancer 1994;69:525-528.
17. Ferdeghini M, Gastellani A, Annicchiarico C, et al. Serum CYFRA21-1 assay in squamous cell carcinoma of the cervix. Anticancer Res 1993;13:1841-1844.
18. Doweck I, Barak M, Greenberg E, et al. Cyfra21-1: a new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 1995;121:177-181.
19. Tsuchiya Y, Onda M, Miyashita M, Sasajima K. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus. Med Oncol 1999;16:31-37.
20. Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer 2000;89: 1413-1417.
21. Brockmann JG, St Nottberg H, Glodny B, et al. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 2000;6:4249-4252.
22. Yamamoto K, Oka M, Hayashi H, et al. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997; 79:1647-1655.
23. Nakamura T, Ide H, Eguchi R, et al. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 1998;11:35-39.
24. Quillien V, Raoul JL, Laurent JF, et al. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma. Oncol Rep 1998;5:1561-1565.
25. Sobin LH, Wittekind CH. UICC TNM classification of malignant tumors. 5th ed. New York: John Wiley & Sons, Inc; 1997.
26. Kitamura S. CYFRA. Rinsho-Kensa 1995;39:1237-1242 (in Japanese).
27. Reinmuth N, Brandt B, Semik M, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002;36:265-270.
28. Ebert W, Dienemann H, Fateh-Moghadam A, et al. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem 1994;32: 189-199.
29. Doweck I, Barak M, Uri N, et al. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 2000; 83:1696-1701.
30. Pujol J, Boher J, Grenier J, Quantin X. Cyrfa21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001;31:221-231.
31. Watine J. Serum Cyfra 21-1 as a co-variable in future NSCLC chemotherapy trials. Lung Cancer 2001;33:89-91.